कृपया अन्य खोज का प्रयास करें
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company’s products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for organ transplant; mdc-WWM for contraception; mdc-STM for malaria; and mdc-IRM for neuroscience. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Rachel Almeras | - | - | Censor |
Elizabeth Kogan | - | 2020 | Supervisory Board Member |
Sabri Markabi | 65 | 2017 | Independent Member of the Supervisory Board |
Philippe Guy | - | 2010 | Independent Chairman of Supervisory Board |
Tone Kvale | 55 | 2022 | Supervisory Board Member |
Virginie Lleu | - | 2016 | Independent Member of Supervisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है